National Drug Early Warning System (NDEWS) Weekly Briefing

NDEWS ORIGINAL CONTENT

The National Drug Early Warning System (NDEWS) Rapid Street Reporting (RSR) team visited Atlanta, GA, on January 28-30, 2022, for the RSR study. The RSR team conducted surveys within public spaces, such as sidewalks near downtown/college campuses, public parks, shopping mall areas, libraries, farmers' markets, and public transportation stops within Atlanta. Participants' (n=151) zip codes included 19 counties throughout the Atlanta Metro Area. Read the full report here or click the image above.

Alert from the NDEWS Web Monitoring Team: Online mentions of Flubromazepam

What was found? A trend of increased discussion for the drug Flubromazepam has emerged on Reddit in Fall 2021 and early 2022.

To what does Flubromazepam refer? Flubromazepam is a benzodiazepine derivative drug commonly sold in NPS markets.

How is it being discussed? Commenters describe the long duration of Flubromazepam's effects. Flubromazepam is part of a larger trend of designer benzodiazepines sold and discussed online in recent years. While the slang term “flubro” is associated with Flubromazepam, it more commonly refers to similar drugs Flubromazolam and Flubrotizolam. Due to this ambiguity, “flubro” mentions were excluded from Flubromazepam counts.

Drug Terms: Flubromazepam.

Methodological Note: Data was collected and analyzed by the NDEWS Web Monitoring Team, led by Dr. Elan Barenholtz and PhD candidate Paul Morris of the Machine Perception and Cognitive Robotics (MPCR) Lab at Florida Atlantic University. Metrics are based on word counts derived from algorithmic monitoring of ~80 drug-oriented Subreddits. No personally identifiable or post-specific information is incorporated in this monitoring process. For more methodological details, see our recent publication.

RECENTLY PUBLISHED

DEA TOX 4th Quarter Report 2021

The Drug Enforcement Administration's Toxicology Testing Program (DEA TOX) is aimed at detecting new psychoactive substances within the US. This publication presents the results of cases analyzed and completed by the Clinical Toxicology and Environmental Biomonitoring laboratory from October 1, 2021 through December 31, 2021. Read the report here.

Overdose deaths involving non-benzodiazepines hypnotic/sedatives in the US: Trend analyses

A study published in Lancet Regional Health examined overdose deaths resulting from non-benzodiazepine and gabapentinoids usage. The study used data from the National Center for Health Statistics (USA). Read the full study here.

Businesses in high drug use areas as potential sources of naloxone during overdose emergencies

A study published in Drug and Alcohol Dependence surveyed business owners and employees located in neighborhoods characterized by high rates of drug use in Baltimore City. Results showed most participants  reported seeing individuals under the influence of drugs (93%), public drug use (80%), and overdose (66%) while at work. 66% of participants had heard of naloxone. Among those who had heard of naloxone, only 39% reported that there was a naloxone kit in the business and 28% of businesses had multiple employees trained to use naloxone. Read the full study here.

IN THE NEWS

Corporate opioid-related payouts now being finalized would top $32 billion

Over the next two weeks, some of the largest US corporations could finalize payouts to victims and governments worth roughly $32 billion. There are two major negotiations nearing completion, with the final settlement plan completed as early as today. Read the full story here.

Postdoctoral Fellowships Available Immediately!

The University of Florida Substance Abuse Training Center in Public Health T32 is seeking applicants for two postdoctoral fellowship openings! 

- Fellowships are sponsored by the National Institute on Drug Abuse, and postdocs receive an annual stipend and health benefits for 2 years. 

- An annual allowance is offered to facilitate attendance at conferences.

- Fellows would work on NDEWS, the ABCD study or other NIDA funded studies with internationally known mentors.

- UF resources include: CTSA; McKnight Brain Institute; Center on Addiction Research and Education; Arts in Medicine; Pain Research and Intervention Center of Excellence; UF Health Cancer Center; Emerging Pathogens Institute; Institute on Aging

- The T32 program is directed by Dr. Linda Cottler, and co-directed by Dr. Sara Jo Nixon.

Questions should be directed to Ms. Tamara Millay at tmillay@ufl.edu. Applications are considered on a rolling basis; the program values the diversity of its applicants.

Share your research, news, and events through our submission form

Share your comments on our newsletter through our feedback form

Follow NDEWS on Twitter: @NDEWSnews